[In vivo testing of a 3-hydroxymethylpyridine hydrogen tartrate matrix tablet. Part 2: Comparison between the in vivo drug release from the matrix form and that from Radecol-tablets (author's transl)].
The release characteristics of 3-hydroxymethylpyridine hydrogen tartrate matrix tablets (3-hydroxymethylpyridine = HMP) were studied in vivo by determining the metabolites excreted in the urine and compared with those of commercially available Radecol tablets. After the liberation of an initial dose, the drug is release little by little from the matrix tablet. The ingested silicone matrix is not altered by the passage through the gastrointestinal tract, it is excreted unchanged. No side-effects were seen after the application of two matrix tablets (approximately 150 mg HMP).
D000328:Adult; D001711:Biotransformation; D003692:Delayed-Action Preparations; D006801:Humans; D008297:Male; D009539:Nicotinic Acids / Q000652:urine; D009540:Nicotinyl Alcohol / Q000008:administration & dosage / Q000378:metabolism* / Q000652:urine; D011725:Pyridines / Q000378:metabolism*; D012828:Silicones; D013607:Tablets; D013997:Time Factors
D003692:Delayed-Action Preparations; D009539:Nicotinic Acids; D011725:Pyridines; D012828:Silicones; D013607:Tablets; D009540:Nicotinyl Alcohol
In-vivo-Testung einer 3-Hydroxymethylpyridinhydrogentartrat-Matrixtablette. 2. Mitteilung: Vergleich der Wirkstoffliberation aus der Matrixform in vivo mit Radecol-Tabletten.